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Abstract
Bone marrow transplantation or ponatinib treatment are currently recommended strategies
for management of patients with chronic myeloid leukemia (CML) harboring the T315I muta-
tion and compound or polyclonal mutations. However, in some individual cases, these treat-
ment scenarios cannot be applied. We used an alternative treatment strategy with
interferon-α (IFN-α) given solo, sequentially or together with TKI in a group of 6 cases of
high risk CML patients, assuming that the TKI-independent mechanism of action may lead
to mutant clone repression. IFN-α based individualized therapy decreases of T315I or com-
pound mutations to undetectable levels as assessed by next-generation deep sequencing,
which was associated with a molecular response in 4/6 patients. Based on the observed
results from immune profiling, we assumed that the principal mechanism leading to the suc-
cess of the treatment was the immune activation induced with dasatinib pre-treatment fol-
lowed by restoration of immunological surveillance after application of IFN-α therapy.
Moreover, we showed that sensitive measurement of mutated BCR-ABL1 transcript levels
augments the safety of this individualized treatment strategy.
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Introduction
In 1983, Talpaz et al [1] introduced interferon-α (IFN-α) as a treatment for chronic myeloid
leukemia (CML), and it became the standard CML therapy in the 90s. IFN-αmodulates gene
expression, promotes cell differentiation and apoptosis, inhibits cell growth and proliferation,
restores regulation by the bone marrow microenvironment and induces an immunomodula-
tory response [2]. However, only 10–20% of treated patients achieved complete cytogenetic
remission (CCgR) associated with prolonged survival [3,4]. Patients who have been success-
fully treated with IFN-α express increased amounts of cytotoxic T lymphocytes (CD8+ T-cells)
and natural killer (NK) cells [5–7].
Targeted therapy with tyrosine kinase inhibitors (TKIs) impairing BCR-ABL1 kinase activ-
ity has greatly improved the outcome of patients with CML and has become the standard first
line treatment since 2001 [8]. Approximately 20–30% of patients, however, develop resistance
during TKI therapy. Approximately half of these resistant cases can be explained by point
mutations in the BCR-ABL1 kinase domain [9, 10]. Notably, all currently available TKIs except
ponatinib fail to overcome the most resistant mutation, T315I. Likewise, the presence of com-
pound mutations, often resulting from sequential TKIs therapy [11, 12], can barely be over-
come by TKIs, including ponatinib [13, 14].
IFN-α treatment still has its place in CML therapy in the TKI area. IFN-α is effective against
dormant CML stem cells, which are resistant to TKI therapy. Essers et al. [15] showed that
IFN-α affected dormant CML cells exit G0 phase and enter the active cell cycle with a mouse
model [15]. Six clinical studies describe the use of IFN-α in combination with TKI to elicit a
sustained deep molecular response and possible TKI therapy cessation [16].
The recommended treatment options for patients with the T315I mutation include ponati-
nib, bone marrow transplantation or clinical studies testing novel compounds [17]. However,
in some individual cases, none of these approaches can be applied. We assumed that an alterna-
tive option was an individualized treatment strategy that eased the selective pressure on the
mutated clone by stopping TKI and administering IFN-α alone, sequentially or together with
TKI. We suggest that TKI sequential therapy with IFN-α or TKI cessation may lead to loosen-
ing of the selective pressure of TKI on the mutant clone that is resistant against TKI, but a non-
mutated clone may emerge. After re-initiation of TKI, the proliferation of the non-mutated
clone is inhibited, but TKI resistant mutant clones may re-emerge. Combination therapy of
IFN-α and TKI yields benefits of both drugs.
In this work, we aimed to follow-up the effect of TKI cessation and solo IFN-α treatment or
the combination of TKI with IFN-α on the reduction in mutant clones as assessed by using
highly sensitive next-generation deep sequencing (NGS) in 6 CML cases, in which this alterna-
tive treatment strategy was applied in clinical practice. Additionally, we analyzed the immune
profiles of patients at specific time points, i.e., before IFN-α initiation and during IFN-α treat-
ment to follow-up the immunomodulatory effects of IFN-α which are supposed to contribute
to the leukemic clone suppression [6, 18].
We showed that individualized IFN-α-based treatment resulted in the reduction of the
T315I and M351T/F317L compound mutation burden to undetectable levels, as assessed by
NGS, and in the achievement of a sustained molecular response in 4/6 high risk CML patients.
Based on the observed immune-profiles, we assume that the immune changes induced by
sequential treatment with the TKI (dasatinib) and IFN-α were crucial for the achievement of
this favorable response. Moreover, we determined an important role for a highly sensitive mea-
surement of BCR-ABL1 mutant mRNA load dynamics by NGS [12,19] for individualized treat-
ment management.
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Material and Methods
Ethics statement
This work was conducted in accordance with the principles of the Helsinki declaration and was
approved by the Ethics Committees of Department of Hematology and Blood Transfusion
Prague, University Hospital Olomouc and 3rd Faculty of Medicine and Faculty Hospital Kra-
lovske Vinohrady. All patients gave their written informed consent prior to this work.NGS
data are available upon request from an Ethics Board or the corresponding autor.
Patients
Six CML patients (5 males and 1 female) (Table 1) were managed in a clinical practice based
on the individual treatment scenarios of administering IFN-α after failure of 2 lines (5 patients)
or 3 lines (1 patient) of TKI treatment due to the development of the highly resistant mutation
T315I or compound mutations, respectively (Table 2). Patients could not switch to ponatinib
due to its unavailability at that time nor could any patient be transplanted for comorbidities or
lack of an HLA-compatible donor.
Standardized measurement of BCR-ABL1 transcript levels
BCR-ABL1 transcript levels were measured regularly every 3 months during the treatment
[20]. Total RNA was prepared from the total leukocytes of peripheral blood by Trizol (Ther-
mofisher scientific, Waltham, MA, USA) lysis-phenol-chloroform extraction; cDNA was syn-
thesized by M-MLV reverse transcriptase (Promega Corporation, Madison, WI, USA) using
random hexamer primers (Jena Bioscience, Jena, Germany). GUSB (in Prague lab) or ABL1 (in
Olomouc lab) were used as the control genes for the standardized quantification of BCR-ABL1
mRNA using reverse-transcriptase qPCR. BCR-ABL1 quantification was standardized in both
labs within the EUTOS for the CML project of ELN, and data are reported in the International
Scale (IS) [21]. Primers and probes for BCR-ABL1, GUSB and ABL1 were applied according to
the Europe Against Cancer recommendations and commercial plasmid standards were used to
perform calibration curves (Ipsogen, Qiagen, Valencia, CA, USA).
BCR-ABL1 mutation detection by next-generation deep sequencing
The dynamics of the mutation load were analyzed both retrospectively and prospectively using
NGS (GS Junior, Roche Applied Science, Basel, Switzerland) of the cDNA region encoding the
kinase domain of BCR-ABL1 in a total of 54 samples (median, 6 samples per patient; range,
Table 1. Patient’s characteristics.
Patient no Diagnosis Sex Age Sokal score Disease duration(months) Response*
1 CML-AP M 44 HR 126 MMR
2 CML-AP F 59 HR 68 MR5
3 CML-CP M 39 HR 62 MR5
4 CML-CP M 23 UN 96 MMR
5 CMP-CP M 80 IMR 44 CHR
6 CML-CP M 65 HR 39 CHR (MMR after current ponatinib treatment)
AP—Accelerated Phase; CP—Chronic Phase; LR- low risk; IMR—intermediate risk; HR-high risk; MMR—Major Molecular Response (BCR-ABL1  1%);
MR5 (deep Molecular Response– 5 log reduction of BCR-ABL1 transcript levels from the standardized baseline); UN- unknown,
*–response to IFN-α individualized therapy
doi:10.1371/journal.pone.0155959.t001
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5–15) of peripheral blood leukocytes according to a previously established protocol [12,19].
Briefly, the mRNA was transcribed using random hexamers and SuperScript II enzyme (Invi-
trogen, Thermofisher scientific,Waltham, MA, USA). In order to analyze the KD of only the
translocated ABL1, a nested PCR approach was used. The first selective amplification was per-
formed with a forward primer located on the BCR exon 13 (5’-TGACCAACTCGTGTGTG
AAACTC-3’) and a reverse primer located on the ABL1 exon 11 (5’-ATCTCAGGCACGT
CAGTGGT-3’). The second amplification step was subsequently performed using 4-amplicon
assays developed and distributed within the framework of the IRON-II phase study (Interla-
boratory RObustness of Next-Generation Sequencing) [22]. The required minimal level of
total BCR-ABL1 transcripts in the analyzed sample was 0.1%IS.
NGS data were evaluated using Amplicon Variant Analyzer software (Roche Applied Sci-
ence) and also using pipeline that was described in the recent paper [19]. For error filtering
(correction for false positive variants) was used algorithm [19] that takes into account distribu-
tion of errors in sequencing data from healthy donor samples in kinase domain of ABL1. Nega-
tive binomial distribution fit to those data was used for error filtering.
Flow cytometry
The basic immune-profiling was performed in 5/6 CML patients using flow-cytometry that
detected populations of CD4+, CD8+, regulatory T-cells (Tregs) and NK cells before IFN-α ini-
tiation and during IFN-α treatment. Peripheral blood samples were stained with anti-CD3
FITC clone MEM-57, anti-CD4 FITC clone MEM-241, anti-CD8 PE clone MEM-31, anti-
CD16+CD56+ PE clones LNK-16 and MEM-188, anti-CD4 APC clone MEM-24 and anti-
CD8 PerCP clone MEM-31 (Exbio Prague, Czech Republic) using a lyse/no-wash protocol.
Minimal acquisition was designated as 10,000 CD3+ events. Intracellular Foxp3 analyses were
performed using a Human Regulatory T Cell Staining Kit (eBioscience, San Diego, CA, USA)
which contains the Foxp3 PE clone PCH101, CD4 FITC and CD25 APC antibodies plus buff-
ers and controls. The staining protocol was optimized with PBMCs. Fresh Ficoll prepped
PBMCs were surface stained with anti- CD25 APC and anti-CD4FITC antibodies and then
subsequently with anti Foxp3 PE antibody (intracellular staining). CD25+CD4+Foxp3+ cells
were considered as T regulatory cells. Minimal acquisition was designated as 10,000
CD25 + CD4+ events. Analysis of immune competent cell subpopulations was performed
using the FACS Diva (BD Biosciences, San Jose, CA, USA) software. Absolute numbers were
expressed as the number of cells ×109/L.
Results
In this group of 6 cases, 5 patients failed therapy due to the acquisition of a T315I mutation,
and one patient failed therapy due to the acquisition of a compound mutation M351T/F317L
during sequential TKI treatment. None of the 6 patients could be switched to ponatinib due to
its unavailability at that time, nor could any patient be transplanted for comorbidities or lack of
an HLA-compatible donor.
TKI stoppage and introduction of an IFN-α based treatment strategy led to a major molecu-
lar response (MMR) or deep MR [23] as well as to undetectable levels of BCR-ABL1T315I and
BCR-ABL1M351T/F317L in 4 patients (patients no 1–4, Table 2 and Fig 1).
In patient no 1 (Fig 1A), 100% of BCR-ABLT315I was retrospectively detected during the
first line of imatinib treatment (at the time the patient failed imatinib, BCR-ABL1 KDmutation
screening using standardized Sanger sequencing was not yet available as a routine diagnostic).
Surprisingly, the patient achieved MMR after the switch to dasatinib, although the total
BCR-ABL1 transcripts were mutated. Because of the molecular progression with the loss of
BCR-ABL1Mutations Disappeared on IFN-α
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Fig 1. Dynamics of total andmutated BCR-ABL1 transcript levels. (A) Patient no 1: The patient achieved
MMR on solo IFN-α and maintained MMR for 88 months; the T315I mutation was persistently undetectable for 62
months due to the overall low levels of total BCR-ABL1 transcripts. (B) Patient no 2: Compound mutations
M351T/F317L (100%) developed after sequential therapy with imatinib and dasatinib. The patient has now been
on IFN-α/nilotinib therapy with undetectable mutations for 29 months. MR5 was achieved on the 15th month of the
BCR-ABL1Mutations Disappeared on IFN-α
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MMR and the confirmed presence of the T315I during dasatinib treatment, the patient was
switched to IFN-αmonotherapy which led to deep MR. During a period of evident BCR-ABL1
transcript level oscillations (from negative to positive levels up to maximum 0.04%IS) (Fig 1),
decreased levels of CD3+ T-lymphocytes and elevated levels of NK cells were observed
(Table 3). These results are comparable with long-term treatment with IFN-α [6]. Although we
do not have data regarding immune profiling during dasatinib treatment, we assume that dasa-
tinib activated immune surveillance, which may explain the MMR achievement despite the
presence of T315I leukemic clones.
The combination of IFN-α/nilotinib was applied for patient no 2 (Fig 1) after failure of ima-
tinib first line and dasatinib second line therapies. IFN-α/nilotinib resulted in the achievement
of MR5, thus, the BCR-ABL1 mutation could not be detected. Elevated levels of NK and
CD8+T cells (Table 3) were detected in this patient, probably representing an immune
combined treatment. (C) Patient no 3: Poor compliance to imatinib treatment within the 24th– 30th month; the
T315I mutation burden decreased on solo IFN-α therapy down to undetectable levels after the combination of
IFN-α and nilotinib. The patient achieved MR5 in the 22nd month from IFN-α treatment initiation. (D) Patient no 4:
The T315I mutation decreased on solo IFN-α therapy and was not detected for the subsequent 46 months on
solo nilotinib therapy. The relatively slow reduction of the BCR-ABL1 transcript level and MMR achievement
might have been caused by a problematic compliance to nilotinib. (E) Patient no 5: The T315I mutation
decreased on solo IFN-α therapy, but the F317L and E255Vmutations appeared and expanded. Death of this
patient was related to lung tuberculosis. (F) Patient no 6: IFN-α therapy did not contribute to the T315I reduction
and response improvement. Therefore, the patient has been switched to ponatinib with CCgR achievement after
7 months from ponatinib treatment initiation. IMA-imatinib, NILO-nilotinib, DASA-dasatinib, IFN-α –interferon
alpha, HU-hydroxyurea, PONA-ponatinib. Note: A mutation burden of 0% represented undetectable levels of
mutated BCR-ABL1 transcripts when the sequencing depth was 1,000 to 8,000 sequence reads per each
nucleotide position.
doi:10.1371/journal.pone.0155959.g001





Therapy CD3+ T- lymphocytes
10^9/l
CD4+ T- helper cells
10^9/l




1 86 IFN 0,787 0,419 0,419 0,140
119 IFN 0,783 0,537 0,290 0,131
122 IFN 1,06 0,532 0,616 0,227
2 20 DASA 0,912 0,572 0,465 0,465
26 DASA 1,164 0,543 0,718 0,66
28 DASA 1,746 0,95 0,95 0,616
32 DASA 1,246 0,659 0,712 0,338
65 IFN
+NILO
1,123 0,343 0,439 0,137
3 38 DASA 0,465 0,268 0,255 0,469
39 DASA 0,808 0,413 0,430 0,705
43 IFN 0,841 0,390 0,369 1,190
57 IFN
+NILO
0,632 0,303 0,320 0,142
4 93 NILO 1,06 0,52 0,48 0,16
96 NILO 1,25 0,66 0,54 0,14
5 42 IMA 1,07 0,72 0,32 0,06
Note: The flow cytometry analysis of patient no 6 could not be performed due to unavailability of samples. IMA-imatinib, NILO-nilotinib, DASA-dasatinib,
IFN -interferon alpha.
doi:10.1371/journal.pone.0155959.t003
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activation by dasatinib treatment followed by restoration of immunological surveillance by
combined IFN-α/TKI treatment.
Solo IFN-α was administered in patient no 3 (Fig 1) after second line dasatinib failure. The
levels of BCR-ABL1T315I decreased, while the total non-mutated BCR-ABL1 transcript levels
increased on solo IFN-α. For this reason, the therapy was changed to the combination of IFN-
α/nilotinib and the patient achieved MR5. This, as well as a previous case, outlined a possible
mechanism of action for both drugs when TKI and IFN-α were co-administered; TKI controls
un-mutated BCR-ABL1 positive clones and IFN-α controls mutated BCR-ABL1 clones exhibit-
ing resistance to TKI. The immunological analysis of patient no 3 could be performed both
during dasatinib therapy and during co-administration of IFN-α/nilotinib. The relative and
absolute representation of CD3+ T-cells was reduced with gradual normalization (Table 3).
The ratio of CD4+/CD8+ T-lymphocytes was constantly reduced and representations of both
populations were generally similar. Importantly, the number of NK cells was markedly accen-
tuated during dasatinib treatment.
IFN-α solo therapy resulted in a decrease of the T315I mutation to undetectable levels in
patient no 4 (Fig 1). Its co-administration with nilotinib was later applied in consideration of
persistently high total BCR-ABL1 mRNA levels. IFN-α was stopped after 8 months due to
undetectable mutations as shown by NGS. The patient has been on solo nilotinib therapy for
46 months, with undetectable T315I (or other) mutations and MMR achievement. Immune
profiling showed slightly accentuated levels of NK cells (Table 3). In this case, we can only
speculate about the involvement of a particular cell fraction to control CML clones.
During IFN-αmonotherapy, the T315I mutation levels were reduced from 100% to 4% in
patient no 5 (Fig 1), but two other mutations appeared (F317L and E255V). This 85-year old
patient died of lung tuberculosis with an overall survival of 44 months. We observed a basic
division of T-lymphocyte fractions during treatment management. The best IFN-α therapy
outcome was described among others in patients younger than 60 years [24]. The enhancing
effect of IFN-α on the immune response was probably deficient in this elderly patient. In addi-
tion, the higher incidence of mutations may be related to advanced age.
The concept of TKI cessation and IFN-α introduction did not contribute to the T315I
reduction or to response improvement in patient no 6 (Fig 1). Recently, it was possible to
switch therapy to ponatinib with a reduction of total BCR-ABL1 transcripts to MMR levels,
which was associated with a simultaneous reduction of T315I.
Discussion
IFN-α CML therapy currently has an important place in CML treatment for its unique activity
against dormant CML stem cells and for its ability to activate the specific immunity that is nec-
essary for a sustained deep molecular response and possible TKI therapy cessation, as is cur-
rently being investigated in clinical trials [2].
In this work, using a series of case reports, we described that stopping TKI treatment and
administering IFN-α alone, sequentially or together with TKI, may lead to reduced selective
pressure by TKI on the mutant clone that is highly resistant against TKIs and that the immuno-
modulatory effect of IFN-αmay suppress leukemic clones, which may contribute to the molec-
ular response achievement.
The switch of TKI to IFN-α-based treatment resulted in decreased mutated BCR-ABL1
mRNAs to undetectable levels in 4/6 patients. Three of those patients achieved a major molecu-
lar response with undetectable BCR-ABL1 mutations. Based on the detection of non-mutated
BCR-ABL1 transcripts, IFN-α remained withdrawn with solo nilotinib in 1/4 patient who also
achieved MMR. One case of an MMR responding patient on solo IFN-α treatment showed
BCR-ABL1Mutations Disappeared on IFN-α
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decreased levels of CD3+ T-lymphocytes and elevated levels of NK cells. Another two patients
who achieved MMR after IFN-α showed elevated levels of NK cells, likely representing
immune activation on dasatinib pre-treatment followed by restored immunological surveil-
lance after the application of combined treatment IFN-α with TKI. In 2/6 cases, TKI cessation
and IFN-α introduction did not contribute to the reduction in BCR-ABL1 mutations or an
improved response.
Expansion of CD8+ T-cells or NK cells was found in a proportion of dasatinib treated
patients and was associated with a superior therapy response [25]. Dasatinib may induce a
reversible state of aberrant immune reactivity by inhibiting immune-regulatory kinases. This
activity is associated with good clinical responses and a distinct adverse effect profile [26].
Kreutzman et al. [6] reported an increased amount of CD8+ T-cells associated with good thera-
peutic outcomes in IFN-α treated patients. A good therapeutic effect of IFN-α therapy is asso-
ciated with an increased amount of NK cells, specifically clonal γδ+ T-cells [6]. We suppose
that the molecular response of patients no 1–3 was induced by the immune activation by dasa-
tinib pre-treatment followed by restoration of immune surveillance after application of IFN-α-
based therapy.
Only 2 case reports on the use of IFN-α in CML treatment in patients with the T315I muta-
tion have been published [18,27]. Here, we report an undisputed positive effect of individual-
ized IFN-α therapy given alone, in combination with TKI or sequentially, on the elimination of
highly resistant mutational clones and in the achievement of a molecular response in 4 cases of
high risk CML patients. The immune response supports the suggestion that IFN-α therapy
after dasatinib pretreatment can help restore activated immune surveillance. In addition to
reducing the TKI selective pressure on mutant clones, this strategy contributed to the achieve-
ment of a molecular response. We believe that the individualized treatment management
described herein using IFN-α as a monotherapy or in combination with a TKI represents an
important alternative treatment strategy in some cases of high risk CML patients that may
have limited options, notably, the inability to receive ponatinib or a bone marrow transplanta-
tion. We also show that the best patient management results from an integrated molecular
approach combining highly sensitive NGS-based analysis of mutation dynamics and standard-
ized RTq-PCR for molecular response monitoring.
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